Market Place
Sourcing Support
NexImmune Announces Closing of $3.67 Million Registered Direct Offering
06 Feb 2024 //
GLOBENEWSWIRE
NexImmune Announces $3.67 Million Registered Direct Offering
02 Feb 2024 //
GLOBENEWSWIRE
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
24 Oct 2023 //
GLOBENEWSWIRE
NexImmune Announces Presentations at Annual Meeting
19 Oct 2023 //
GLOBENEWSWIRE
NexImmune Announces 1-for-25 Reverse Stock Split
18 Oct 2023 //
GLOBENEWSWIRE
NexImmune to lay off 53% of employees to save money, CFO to step down
01 Sep 2023 //
#N/A
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle
31 Aug 2023 //
GLOBENEWSWIRE
NexImmune Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
22 May 2023 //
GLOBENEWSWIRE
NexImmune Reports 1Q 2023 FYR Results and Provides Business Updates
15 May 2023 //
GLOBENEWSWIRE
NexImmune Announces Presentation of Ph 1/2 Clinical Data at the 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy
16 Feb 2023 //
GLOBENEWSWIRE
NexImmune Announces Publication in Frontiers in Medicine
18 Jan 2023 //
GLOBENEWSWIRE
Hutchmed, NightHawk and NexImmune drop R&D programs
15 Nov 2022 //
FIERCEBIOTECH
NexImmune Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
NexImmune Announces Research Collaboration with (NINDS) of (NIH)
06 Oct 2022 //
GLOBENEWSWIRE
NexImmune to Present at the H.C. Wainwright Global Investment Conference
09 Sep 2022 //
GLOBENEWSWIRE
Selexis and NexImmune Sign Service Agreement
08 Sep 2022 //
BUSINESSWIRE
NexImmune cites tough competition for pausing myeloma plans
17 Aug 2022 //
FIERCEBIOTECH
NexImmune Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
NexImmune Announces IND Clearance by US FDA for NEXI-003
14 Jul 2022 //
GLOBENEWSWIRE
NexImmune Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
10 May 2022 //
GLOBENEWSWIRE
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
10 May 2022 //
GLOBENEWSWIRE
NexImmune Announces Preclinical Research Collaboration with Columbia University
26 Apr 2022 //
GLOBENEWSWIRE
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
14 Apr 2022 //
GLOBENEWSWIRE
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology
17 Mar 2022 //
GLOBENEWSWIRE
NexImmune Enters Collaboration with NYU Langone`s Cancer Center
14 Mar 2022 //
GLOBENEWSWIRE
NexImmune to Present at the Barclays 2022 Global Healthcare Conference
10 Mar 2022 //
GLOBENEWSWIRE
NexImmune Reports Q4 and FY 2021 Financial Results
09 Mar 2022 //
GLOBENEWSWIRE
NexImmune Appoints Kristi Jones as CEO and Member of the Board of Directors
17 Feb 2022 //
GLOBENEWSWIRE
NexImmune Collaborates with Rutgers, Related to Neuroendocrine Tumor Targets
01 Feb 2022 //
GLOBENEWSWIRE
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results
12 Dec 2021 //
GLOBENEWSWIRE
NexImmune Reports Q3 2021 Financial Results and Provides Business Updates
12 Nov 2021 //
GLOBENEWSWIRE
NexImmune Strengthens Management Team with Key Appointments
14 Jul 2021 //
GLOBENEWSWIRE
NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data
18 May 2021 //
GLOBENEWSWIRE
Immunotherapy biotech NexImmune ups share offering by 25% ahead
11 Feb 2021 //
NASDAQ
NexImmune Announces Pricing of Upsized Initial Public Offering
11 Feb 2021 //
GLOBENEWSWIRE
Immunotherapy biotech NexImmune files for an $86 million IPO
20 Jan 2021 //
NASDAQ
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001
07 Dec 2020 //
GLOBENEWSWIRE
NexImmune to Highlight Preliminary Results from Ph1/2 Trial of NEXI-001
04 Nov 2020 //
GLOBENEWSWIRE
NexImmune Establishes Research Initiative with City of Hope to Focus
27 Oct 2020 //
GLOBENEWSWIRE
1st Patient Dosed in NexImmune Ph1/2 Clinical Trial of NEXI-002
06 Oct 2020 //
GLOBENEWSWIRE
NexImmune Completes Dosing of in Clinical Trial of NEXI-001 in Relapsed AML
23 Sep 2020 //
GLOBENEWSWIRE
